Home
overview

Considerable progression has been made in immunogenicity over recent years, with innovative developments seen in predicting and controlling immunogenicity. Complex challenges to industry remain however.

At SMi’s 4th annual Immunogenicity conference, industry, regulatory and academic experts will gather to spark debate and progress on the causes of immunogenicity, predicting and preventing its effects, and its associated issues. Immunogenicity 2017 will offer unparalleled networking opportunities, deep insight into industry issues, and spotlight sessions on innovations and emerging technologies for immunogenicity.

Immunogenicity 2017 will explore the need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. We will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for our delegates, Immunogenicity 2017 will highlight and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

• Guidance on UK, EU and USA regulations surrounding immunogenicity and best practice risk assessment
• Targeted focus on immunogenicity; identifying, addressing and removing challenges to industry
• Highlight best practise risk assessment and mitigation through high level case studies
• Explore novel and innovative approaches to reducing immunogenicity
• Spotlight on new technology; Humanising proteins and new biotherapeutic solutions
• Personalising treatments with next generation biologic drugs
 

Directors, Group Leaders, Department Heads, Senior Scientists of: 

  • Immunogenicity
  • Immunology
  • Regulatory Affairs
  • Biologic Drugs
  • Pre Clinical Risk Assessment
  • Drug Development
  • Clinical Development

Abzena; Accord Healthcare; Baliopharm AG; Baxalta; Bioarctic Neuroscience; Bristol Myers Squibb; Crucell Vaccine Institute; EpiVax, Inc.; F.Hoffmann-La Roche AG; Free University Of Brussels; GSK; ImmunXperts; ISA Pharmaceuticals; mAbxience; Medimmune LLC; National Institute for Biological Standards and Control; Netera AS; NEXTERA AS; NIBSC; Pfizer; Pfizer Pharmaceuticals; ProImmune Ltd.; Public Health England; Selecta Biosciences; SGS CEPHAC EUROPE SAS; Smithers Avanza; Teva; TIGENIX SAU; UCB; University Of Manchester;

FEATURED SPEAKERS

Kei Kishimoto

Kei Kishimoto

Chief Scientific Officerá, Selecta Biosciences Inc.
Oreda Boussadia

Oreda Boussadia

European Head of Business Development & Strategy, EpiVax, Inc.
Sofie Pattijn

Sofie Pattijn

Chief Technology Officer, ImmunXperts

Albert Torri

Senior Director, Bioanalytical Sciences, Regeneron Pharmaceuitcals Inc
Albert Torri

Albert Torri is the Executive Director of Bioanalytical Sciences at Regeneron Pharmaceuticals in Tarrytown, NY. He received his Ph.D. in Biochemistry from the University of Alabama at Birmingham and conducted his post-doctoral studies at Johns Hopkins University. He then joined the Bristol-Myers Squibb Company where he served as a Senior Research Investigator and member of the Discovery Working Group. In his current position at Regeneron Pharmaceuticals, he directs assay development and bioanalytical activities. Responsibilities include the development, validation and automation of PK, PD and immunogenicity assays to support preclinical and clinical studies of biologics, as well as the bioanalysis of all preclinical and clinical study samples using these assays.

Annie De Groot

CEO/CSO, EpiVax, Inc.
Annie De Groot

Chloe Ackaert

Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
Chloe Ackaert

Ivo Sonderegger

Project Manager , Boehringer Mannheim GmbH
Ivo Sonderegger

Jeremy Fry

Director of Sales, ProImmune Ltd.
Jeremy Fry

John Smeraglia

Senior Director, Bioanalytical Sciences , UCB
John  Smeraglia

Katharine Bray-French

Toxicology Project Leader, Roche Pharma Research & Early Development
Katharine Bray-French

Kei Kishimoto

Chief Scientific Officerá, Selecta Biosciences Inc.
Kei Kishimoto

Louis Boon

Chief Scientific Officer, Bioceros
Louis Boon

Matthias Hofmann

, Novartis Institutes for BioMedical Research
Matthias Hofmann

1992 – 1999: Diploma in Biochemistry (Studies in Würzburg, Germany, Tübingen, Germany & Austin, TX, USA)
1999 – 2002: PhD in Immunology (University of Tübingen)
2002 – 2005: PostDoc in Transplanation Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
2005 – present: LabHead in Bioanalytics & Immunogenicity, Novartis Institutes for BioMedical Research, Basel, Switzerland

Meenu Wadhwa

Section Leader, Cytokines & Growth Factors Section, NIBSC
Meenu Wadhwa

Meenu Wadhwa is Section Leader, Cytokines and Growth Factors Section in the Biotherapeutics Group at the National Institute for Biological Standards and Control (NIBSC). She is responsible for a number of diverse projects in the cytokine and growth factor area. These include preparation of cytokine standards and/or reference reagents for WHO and Pharmacopoeias, development, and implementation of cytokine assays and their use in standardization, product testing and in research. Main research interests include development of novel bioassays for cytokines, cytokine contamination of biological products and the unwanted immunogenicity of biotherapeutic products. This has resulted in over 90 publications in scientific journals/books and several presentations at international/ national scientific conferences. She has contributed to several guidelines, for example, the drafting of the EMA guidelines on immunogenicity assessment and WHO guidelines on Evaluation of Similar Biotherapeutic Products. She reviews manuscripts for several scientific journals and is currently an editorial board member for Journal of Immunological Methods and an associate editor for Biologicals.

Melody Sauerborn

Freelance Trainer, Pharmaceutical Training International
Melody Sauerborn

Oreda Boussadia

European Head of Business Development & Strategy, EpiVax, Inc.
Oreda Boussadia

Rob Caldwell

Principal Research Scientist, Regulatory Toxicology, AbbVie
Rob Caldwell

Rob is a toxicologist at AbbVie, where he has worked for the last 10 years. Rob’s main responsibility is to manage the preclinical toxicology strategy for drug development teams, supporting the overall safety assessment of new drugs. He works primarily on rheumatologic therapies but has also worked with antivirals and pain therapies. Prior to joining AbbVie, Rob worked at Covance Laboratories (a contract research laboratory) for 8 years where he lead the immunotoxicology program and conducted general toxicology studies for the pharmaceutical industry. Rob obtained his PhD in Immunology from Northwestern University in Chicago; where he studied mechanisms of Epstein-Barr virus latency and reactivation using transgenic mice.

Sofie Pattijn

Chief Technology Officer, ImmunXperts
Sofie Pattijn

Sophie Tourdot

Scientific Project Manager, INSERM
Sophie Tourdot

Vibha Jawa

Director Biologics and Vaccine Development , Merck & Co.
Vibha Jawa

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.